
No Data Available
|
Tissue Therapies Limited (TIS)
is a publicly listed company on the Australian Securities Exchange (ASX).
Company Announcements
No Company Announcements
General Overview
About Tissue Therapies Limited
Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.
Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology.
The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate.
Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.
Tissue Therapies is currently focused on launching VitroGro® ECM in Europe and preparing the way for entering the USA and rest of world markets. In addition, the company is driven to expand its product line by exploring additional indications (use) of VitroGro® ECM while developing new intellectual property and new products.
Growth Strategy
They see opportunities to have significant impact in wound care markets in Asia, Australia, Canada, Europe, New Zealand, the United States and other markets experiencing the economic burden of wound care. They are also continuing to work with their research and development partners to create more effective, complimentary products for wound care and tissue repair.
Commercialisation Strategy
Tissue Therapies Limited:
- Has exceptional clinical trial data and entered into a commercial partnership with Quintiles for sales of VitroGro® ECM in Europe.
- Is proceeding with regulatory approvals and reimbursement approvals in the Company's name.
- Has successfully completed commercial scale GMP manufacturing and has realised inventory in readiness for sale.
- Is proceeding with development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.
Products
VitroGro® ECM
VitroGro® ECM is a sterile, acellular biomimetic scaffold for the treatment of hard-to-heal wounds, primarily venous leg ulcers. VitroGro® ECM replaces degraded wound matrix. VitroGro® ECM binds to a prepared wound bed and provides a scaffold for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as, cell proliferation and migration. VitroGro® ECM improves wound closure and reduces pain thereby improving wound care.
Chronic, hard to heal wounds are characterised by prolonged inflammation that degrades ECM components and senescent skin cells with a reduced capacity to maintain the balance of the ECM.
VitroGro® ECM replaces the degraded ECM in a chronic wound bed by forming a physical surface matrix by adsorption to damaged ECM in the wound bed. VitroGro® ECM is designed to be sticky to assist with adherence to the wound bed. Adhesion of skin cells in the wound to a functional ECM is a primary requirement for subsequent cell functions critical to wound healing, such as proliferation, migration, cell survival, and synthesis of new ECM. If cell attachment does not occur, these functions are not possible. The scaffold provided by VitroGro® ECM is a structure for cellular attachment and proliferation, leading to regeneration of the body's natural ECM. Newly attached cells in the wound bed subsequently produce new native ECM, which in turn, serves to guide normal tissue renewal, maturation and thereby restore healing.
Price History
52 Week High | Change from 52 Week High | % Change from 52 Week High | 52 Week Low | Change from 52 Week Low | % Change from 52 Week Low |
---|---|---|---|---|---|
${{quote["Year's High"]}} | ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} | {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% | ${{quote["Year's Low"] | setDecimalCheckForNa}} | ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} | {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}% |
Upcoming Dividends
Organization Details | RIC | Dividend Amount | Ex Dividend Date | Dividend Payment Date | Yield | Franking % | Earnings | Current Price |
---|---|---|---|---|---|---|---|---|
{{UpcomingDividends[0]['Display Name']}} | {{UpcomingDividends[0].RIC}} | {{UpcomingDividends[0].Dividend}} | {{UpcomingDividends[0]['Ex-Dividend Date']}} | {{UpcomingDividends[0]['Dividend Date']}} | {{UpcomingDividends[0]['Yield']}} | {{UpcomingDividends[0]['GEN VAL2']}} | {{UpcomingDividends[0].Earnings}} | {{UpcomingDividends[0]['CF Last Price']}} |
The next upcoming dividend date has not yet been announced - Please watch this place for updated dividend information |
Historical Dividends
Dividend Yield | Dividend Yield (5 Yr Avg) | ISIN | Stock Code (RIC) | SEDOL | Dividend Currency |
---|---|---|---|---|---|
{{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} | {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} | {{Dividends[0].ISIN}} | {{Dividends[0].RIC}} | {{Dividends[0].SEDOL}} | {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}} |
Year | CorpActID | DPTD | DivAnnDate | DivExDate | DivPayDate | DTMD | DivRate | DRD | DRPrice | DTMD | DTMD | Frank% |
---|---|---|---|---|---|---|---|---|---|---|---|---|
{{item.DividendExDate == '01/01/1900' ? '-' : item.DividendExDate| date : 'dd/MM/yyyy'}} | {{item.CorporateActionsID}} | {{item.DividendPaymentTypeDescription}} | {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate| date : 'dd/MM/yyyy'}} | {{item.DividendExDate == '01/01/1900' ? '-' : item.DividendExDate| date : 'dd/MM/yyyy'}} | {{item.DividendPayDate == '01/01/1900' ? '-' : item.DividendPayDate| date : 'dd/MM/yyyy'}} | {{item.DividendTypeMarkerDescription}} | {{item.DividendRate != '0' ? item.DividendRate : '-'}} | {{item.DividendReinvestmentDeadline == '01/01/1900' ? '-' : item.DividendReinvestmentDeadline| date : 'dd/MM/yyyy'}} | {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} | {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} | {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} | {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}} |
Financial Reports
Financial Summary
Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}
{{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}
Accounting Notes
Fiscal Year Ends | Most Recent Quarter | Transfer agent | Auditor | Shariah Compliant |
---|---|---|---|---|
{{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }} - |
- | - | {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}} |
Fiscal Period | |
Period End Date: | |
Period Length | |
Ratios | Value |
Analyst Footnotes
Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}
{{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}
Directors, Officers & Company Executives
Start Date | End Date | |
---|---|---|
{{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}} | ||
{{persontitlesobject.Value}}, | {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} | {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}} |
No Directors, Officers & Company Executives Information Found. |
Recommendation Statistics
No Recommendation Statistics
Recommendation Statistics | ||
---|---|---|
Recommendation | Number Of Analysts | |
Sell Reduce Hold Buy Strong Buy | {{stats.NumberOfAnalysts}} |
I/B/E/S Mean | ||
---|---|---|
{{verdict[meanmarker]}} | {{analystvotes}} Analysts | Mean recommendation from all analysts covering the company on a standardized 5-point scale. |
|
Past Broker Recommendations
No Past Recommendations
Past Broker Recommendations | ||||||
---|---|---|---|---|---|---|
Sell | Underperform | Hold | Buy | Strong Buy | Total | |
{{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} | {{snapshots.Statistics[0].NumberOfAnalysts}} | {{snapshots.Statistics[1].NumberOfAnalysts}} | {{snapshots.Statistics[2].NumberOfAnalysts}} | {{snapshots.Statistics[3].NumberOfAnalysts}} | {{snapshots.Statistics[4].NumberOfAnalysts}} | {{snapshots.NumberOfRecommendations}} |
Target Price
No Target Price
Target Price | |
---|---|
Mean | {{priceTarget.Mean}} |
High | {{priceTarget.High}} |
Low | {{priceTarget.Low}} |
Median | {{priceTarget.Median}} |
Standard Devitation | {{priceTarget.StandardDeviation}} |
Number Of Estimates | {{priceTarget.NumberOfEstimates}} |
Videos
No Videos Found
{{video.summary}}
Company Reports
No Company Reports
Website Links
Contact Info
Tissue Therapies Limited
L19
179 Turbot Street
Brisbane,
QLD
Australia, 4000
Phone:
+61 7 3334 3900
Fax:
+61 7 3334 3999
Website:
http://www.tissuetherapies.com
Important Information
The General Overview, Services, Products and Projects information for this profile was last edited on 18 Mar 2015.